<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00269607</url>
  </required_header>
  <id_info>
    <org_study_id>11899</org_study_id>
    <nct_id>NCT00269607</nct_id>
  </id_info>
  <brief_title>Naltrexone Implants as Relapse Prevention</brief_title>
  <official_title>Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oslo</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to study the efficacy and safety of naltrexone implants&#xD;
      as relapse prevention for patients that are completing treatment for opiate addiction in&#xD;
      inpatient (or similarly controlled) settings. Participants in the naltrexone experimental&#xD;
      group are prematched in a pairwise fashion with other patients who do not want a naltrexone&#xD;
      implant during the first six months after ending inpatient treatment, but who reiceive&#xD;
      treatment as usual (TAU) from the Norwegian healthcare system.&#xD;
&#xD;
      The hypotheses are that quality of life, depression, opioid use, will be significantly better&#xD;
      in the naltrexone group compared to the non at 6-, 12-, and 18-month follow-up.&#xD;
&#xD;
      We also hypothesize that the implants can prevent death from opioid overdose up to 6 months&#xD;
      after commenced treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment difficulties. Reframed as pilot study&#xD;
  </why_stopped>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcomes: drug use at 6(12/18)months by self report, hair analysis; days in work or education, number of drug-free friends at 6 (12/18)months by self report</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcomes: depression at 6(12/18)months by BDI and Hopkins SCL-25; quality of life at 6(12/18)months by EuropASI</measure>
  </secondary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Opioid Dependency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Implantation of naltrexone implants</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  soon to complete inpatient treatment for opioid addiction&#xD;
&#xD;
          -  living in southern Norway&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  psychosis / major depression, currently not treated&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  liver enzymes: ASAT or ALAT &gt; threefold above upper boundary&#xD;
&#xD;
          -  maintenance treatment with methadone or buprenorphine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helge Waal, professor</last_name>
    <role>Study Director</role>
    <affiliation>Unit for addiction medicine, Institute of psychiatry, University of Oslo</affiliation>
  </overall_official>
  <removed_countries>
    <country>Norway</country>
  </removed_countries>
  <verification_date>December 2005</verification_date>
  <study_first_submitted>December 22, 2005</study_first_submitted>
  <study_first_submitted_qc>December 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2005</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <name_title>University of Oslo, Institute of Psychiatry, Professor Edvard Hauff</name_title>
    <organization>Institute of Psychiatry, University of Oslo</organization>
  </responsible_party>
  <keyword>Substance abuse</keyword>
  <keyword>Treatment</keyword>
  <keyword>Relapse prevention</keyword>
  <keyword>opioid antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

